Peak-Muscle.com  

Welcome to the Peak-Muscle.com forums.

You are currently viewing our boards as a guest which gives you limited access to view most discussions and access our other features. Come join us in on one of the best online fitness communities. We have 16,000 members that are likeminded towards a fitness, bodybuilding lifestyle. Registration is free and only takes but a few minutes. By joining our free community you will have access to communicate privately with other members (PM), respond to polls, upload content and access many other special features. You will be able to create threads to discuss and or create a fitness regimen. Or just bounce ideas off of some very knowledgeable members. So don't miss out. Registration is fast, simple and absolutely free so please, join our community today!

Register FAQ Members List Calendar Arcade Mark Forums Read
Go Back   Peak-Muscle.com > Anabolic Steroid Discussion > Post cycle therapy
User Name
Password

Reply
 
Thread Tools Display Modes
Old 06-09-2011, 05:58 PM   #1
liftsiron
Administrator
 
liftsiron's Avatar
 

Join Date: Nov 2003
Location: Cimmeria
Posts: 17,005
liftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud ofliftsiron has much to be proud of
The effects of anti-e's and AI's on the axis and gyno!

The effects of anti-e's and AI's on the axis and gyno!
Old 16-Oct-2005, 09:04 PM #1
Big'r

Clomid
Clomid increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone (C1-C16, C21, C22).
Clomid response decreases significantly with aging (C1, C7, C11, C13).
Long term treatment with Clomid is effective in normalising a suppressed axis:
-4 months Clomid for 178 men with secondary hypogonadism significantly increases lh - leutenizing hormone - and free testosterone in all patients (C1).
-2 months Clomid for 17 men with secondary hypogonadism significantly elevates lh - leutenizing hormone - , FSH - follicle stimulating hormone - and free testosterone levels (C4).
-12 months 25 mg/day Clomid for 23 men with fertility problems increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone levels during the treatment (C8).
-3 months 50 mg/day Clomid for 5 oligozoospermic men causes a significant rise in serum testosterone (C15).
Short term Clomid treatment is effective in normalising a suppressed axis:
-5 days Clomid for 45 men significantly increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and serum testosterone (C2).
-1 week 100 mg/day Clomid for 42 men with kidney problems increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone levels in all subjects (C6).
-1 week Clomid for 21 men with erectile complaints increases gonadotropin and testosterone levels (C7).
-3 weeks 100 mg Clomid/day for 5 men increases lh - leutenizing hormone - + FSH - follicle stimulating hormone - 3-fold, and circulating testosterone 2-fold (C10).
-11 days 100 mg Clomid for 10 normozoospermatic, 29 oligozoospermatic and 11 azoospermatic men significantly increases FSH - follicle stimulating hormone - , lh - leutenizing hormone - and testosterone (also androstenedione and sex hormone binding globulin ) (C14).
Clomid stimulates the axis in small amounts:
-25 mg/day Clomid for 12 months in 23 men with fertility problems increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone levels during the treatment. Clomid treatment also results in greater lh - leutenizing hormone - , FSH - follicle stimulating hormone - and T responses to GnRH (C8, C8b).
-25 mg/day Clomid for 25 days in 30 men with idiopathic male infertility increases lh - leutenizing hormone - 1,90 x, FSH - follicle stimulating hormone - 1,81 x and testosterone 1,89 x (C9).
Clomid increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone above basal levels:
-5 days Clomid for 45 men significantly increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and serum testosterone (C2).
-1 week 100 mg/day Clomid for 9 healthy males increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone levels in all subjects (C6).
-8 weeks 100 mg Clomid for 10 normal men significantly increases testosterone and non-sex hormone-binding globulin bound testosterone (C11).
-Clomid increases lh - leutenizing hormone - and testosterone and increases pulse amplitude in normal men (C12).
-Clomid for 7 days in 55 healthy men increases mean serum total T and non-sex hormone binding globulin -bound levels in young men (22-35 yr) by 100% and 304%. In older men (65-84 yr) these values increased by only 32% and 8%. (C13).
Clomid increases estrogen levels
-25 mg/day Clomid for 12 months in 23 men with fertility problems increases estradiol levels during the treatment (C8).
-3 weeks 100 mg Clomid/day for 5 men increases circulating estradiol levels 2-fold (C10).
-50 mg/day Clomid for 1-3 months in 5 boys increases estradiol significantly (C21).
-100 mg/day Clomid in 22 boys increases estradiol levels during therapy (C22).
-100 mg/day Clomid for 10 days in 21 normospermic and 36 oligozoospermic men increases estradiol (+60.8%) vs. (+58.8%-118.9%). A similar reaction of estradiol was shown in the hcg stimulation (C31).
-8 weeks 100 mg Clomid for 10 normal men significantly increases estradiol (C11).
-Clomid does not differ estradiol in normal men (C12).
-11 days 100 mg Clomid for 10 normozoospermatic, 29 oligozoospermatic and 11 azoospermatic men significantly increases estradiol (C14).
-3 months 50 mg/day Clomid for 5 oligozoospermic men causes a significant rise in serum E2 (C15).
-100-200 mg Clomid for 4 weeks, or 100 mg for 8 weeks increases estradiol (C16).
Clomid decreases suppression of chemically reduced lh - leutenizing hormone - levels:
-(Cetrorelix blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls the release lh - leutenizing hormone - .)
(40 patients) Clomid in combination with gonadotropins and 0.25 mg of Cetrorelix provides significantly higher lh - leutenizing hormone - concentrations than only gonadotropins and 0.25 mg of Cetrorelix (C3).
Combined Clomid and hcg administration:
-A single dose of (5000 i.u. i.m.) hcg was administrated before and after 3 months of 50 mg Clomid/day in 5 oligozoospermic men. Before the CC-treatment normal responses to hcg were seen (significantly elevated E2 levels at 1 day and T levels at 4 days). After CC, only the concentrations of 17-OHP4 rose significantly following hcg administration (C15).
Following Clomid administration a single dose of (5000 i.u. i.m.) hcg (C15).
Clomid not fit enough to treat gynecomastia. At least in small doses.
-12 boys with persistent gynecomastia used 50 mg Clomid for 1-3 months. Only 5 boys experienced a reduction of > 20% (C21).
-22 boys with gynecomastia used 100 mg Clomid/day. 14 (64%) responded within 6 months (C22).



C1) http://www.ncbi.nlm.nih.gov/entrez/q...801&query_hl=1
C2) http://www.ncbi.nlm.nih.gov/entrez/q...089&query_hl=1
C3) http://www.ncbi.nlm.nih.gov/entrez/q...125&query_hl=1
C4) http://www.ncbi.nlm.nih.gov/entrez/q...597&query_hl=1
C5) http://www.ncbi.nlm.nih.gov/entrez/q...694&query_hl=1
C6) http://www.ncbi.nlm.nih.gov/entrez/q...872&query_hl=1
C7) http://www.ncbi.nlm.nih.gov/entrez/q...138&query_hl=1
C8) http://www.ncbi.nlm.nih.gov/entrez/q...318&query_hl=1
C8b) http://www.ncbi.nlm.nih.gov/entrez/q...318&query_hl=1
C9) http://www.ncbi.nlm.nih.gov/entrez/q...618&query_hl=1
C10) http://jcem.endojournals.org/cgi/con...e2=tf_ipsecsha
C11) http://www.ncbi.nlm.nih.gov/entrez/q...692&query_hl=1
C12) http://www.ncbi.nlm.nih.gov/entrez/q...207&query_hl=1
C13) http://www.ncbi.nlm.nih.gov/entrez/q...649&query_hl=1
C14) http://www.ncbi.nlm.nih.gov/entrez/q...739&query_hl=1
C15) http://www.ncbi.nlm.nih.gov/entrez/q...381&query_hl=1
C16) http://www.ncbi.nlm.nih.gov/entrez/q...529&query_hl=1
C21) http://www.ncbi.nlm.nih.gov/entrez/q...910&query_hl=1
C22) http://www.ncbi.nlm.nih.gov/entrez/q...752&query_hl=1
C31) http://www.ncbi.nlm.nih.gov/entrez/q...734&query_hl=1



Nolvadex
The way Nolvadex works:
Nolvadex can activate neural timing mechanism(s) that govern the intermittent release of endogenous GnRH. 20 mg Nolvadex/day for 7 days in 6 normal men attenuates the ability of exogenous GnRH to increase the bio/immuno lh - leutenizing hormone - ratio further, which suggests the attainment of maximal enrichment in endogenous lh - leutenizing hormone - bioactivity in the presence of antiestrogen (N4).
Nolvadex increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone values (N1-N4, N24, N29)
Long term treatment with Nolvadex is effective in normalising a suppressed axis:
-6 months 20 mg Nolvadex/day for 220 men with oligozoospermia increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone (N1).
-5,5 months 5-20 mg Nolvadex/day for 12 men with oligozoospermia increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone (N3).
-2-4 months Nolvadex for 6 men increases lh - leutenizing hormone - levels significantly (N24).
-2-12 months Nolvadex for 8 boys increases testosterone. lh - leutenizing hormone - showed an increased response to lh - leutenizing hormone - -RH (N29).
Short term Nolvadex treatment is effective in normalising a suppressed axis:
-1 week 20 mg Nolvadex/day for 4 men causes a moderate increase in lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone (N2).
Nolvadex stimulates the axis in small amounts:
-5, 10 and 20 mg Nolvadex/day significantly increases basal testosterone levels and the responses of lh - leutenizing hormone - /FSH - follicle stimulating hormone - to LHRH infusion. Without significant differences between the lower (5-10 mg) or higher doses (20 mg) (N3).
Nolvadex increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone above basal levels:
-20 mg Nolvadex/day for 1 week increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone in 4 normal men (N2).
-40 mg Nolvadex/day for 10 days in 8 normal men increases basal bioactive lh - leutenizing hormone - concentrations from (42.7 +/- 6.9) to (97.6 +/- 19.4) mIU/ml. Total serum testosterone increases significantly (approx. 1.4-fold) (N4).
Nolvadex increases estrogen levels
-5,5 months Nolvadex for 12 men does not significantly influence estradiol levels or the E2 over testosterone ratio (N3).
-2-4 months Nolvadex for 6 men increases total estradiol levels significantly (N24).
-2-12 months Nolvadex for 8 boys increases estradiol (N29).
Nolvadex appears effective in treating gynecomastia. Raloxifene possibly is even more effective.
-(13 men with painful gynecomastia) 10 mg nolva/day for 3 months provided a good response in 10 patients (N21).
-(36 men) 20 mg nolva/day for 6-12 weeks resolved the mass in 30 patients (83,3%). Lump gynecomastia was more responsive than the fatty type (100% vs. 62.5%) (N22).
-(23 men) 20 mg nolva/day provided complete resolution of gynecomastia in 18 patients (78,2%). 400 mg danazol provided complete resolution in only 8 out of 20 patients (40%) (N23).
-(6 men with painful gynecomastia) nolva for 2-4 months provided only marginally significant size reduction (N24).
-(61 men with gynecomastia) 40 mg nolva/day for 2 months provided complete regression of breast swelling in 80% (N25).
-(38 boys with persistent gynecomastia) nolva for 3-9 months reduces breast nodule diameter 2,1 cm. For raloxifene this was 2,5 cm. nolva provided a significant decrease (<50%) in 41%, with raloxifene this was (86%) (N27).
-(10 boys with pubertal gynecomastia) 20-40 mg nolva/day for 2-12 months decreases gynecomastia totally in 8 boys (N29).
Effect Nolvadex on heart and cholesterol in "normal" people seems positive, in women with breast cancer conflicting:
-40 mg Nolvadex for 8 weeks in 16 men with coronory artery disease increases %ED-FMD and decreases several plasma cardiovascular risk factors (N11).
-10 mg Nolvadex for 1 and 3 months in 15 healthy boys effects blood lipids and hemostasis similar, but lesser than described in women (N12).
-Nolvadex for 6 months in 54 women treated for breast cancer increases HDL-C/total-Cholesterol ratio which might lead to an increased cardiovascular risk (N13).
-Nolvadex for 3 + 6 months in 80 women with breast cancer: 38 premenopausal women showed no significant variation in serum lipoprotein profiles, 42 postmenopausal women showed significant improvement in serum lipoprotein profiles (N14).
-Nolvadex for 2 months in 16 postmenopausal women with breast cancer shows marked hypertriglyceridemia in 3/16 patients (N15).
-20 mg Nolvadex for 2 years in 57 normal postmenopausal women reduces the levels of atherogenic lipids and fibrinogen which may substantially reduce the risk o cardiovascular disease (N16).
Side effects Nolvadex
-(13 men) 10 mg nolva/day for 3 months. One patient developed calf tenderness and stopped the medication. No other adverse effects were reported (N21).
-(61 men) 40 mg nolva/day. No long term side effects were observed over a 3 year follow-up period (N25).
-(38 boys) Nolvadex for 3-9 months did not show any side effects (N27).
-(8 boys) Nolvadex for 2-12 months did not show any side effects (N29).


N1) http://www.ncbi.nlm.nih.gov/entrez/q...572&query_hl=1
N2) http://www.ncbi.nlm.nih.gov/entrez/q...972&query_hl=1
N3) http://www.ncbi.nlm.nih.gov/entrez/q...502&query_hl=1
N4) http://www.ncbi.nlm.nih.gov/entrez/q...&dopt=Abstract
N11) http://www.ncbi.nlm.nih.gov/entrez/q...075&query_hl=1
N12) http://www.ncbi.nlm.nih.gov/entrez/q...091&query_hl=1
N13) http://www.ncbi.nlm.nih.gov/entrez/q...&dopt=Abstract
N14) http://www.ncbi.nlm.nih.gov/entrez/q...&dopt=Abstract
N15) http://jcem.endojournals.org/cgi/content/full/83/5/1633
N16) http://jcem.endojournals.org/cgi/con...act/80/11/3191
N21) http://www.ncbi.nlm.nih.gov/entrez/q...589&query_hl=1
N22) http://www.ncbi.nlm.nih.gov/entrez/q...718&query_hl=1
N23) http://www.ncbi.nlm.nih.gov/entrez/q...345&query_hl=1
N24) http://www.ncbi.nlm.nih.gov/entrez/q...557&query_hl=1
N25) http://www.ncbi.nlm.nih.gov/entrez/q...552&query_hl=1
N27) http://www.ncbi.nlm.nih.gov/entrez/q...910&query_hl=1
N29) http://www.ncbi.nlm.nih.gov/entrez/q...765&query_hl=1


Arimidex + Femara
Arimidex increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone values (A1-6)
-1 mg/day Arimidex for 2 weeks in 10 men with IHH normalises levels of testosterone, lh - leutenizing hormone - and estradiol (A4).
Arimidex response decreases significantly with aging (A2).
Arimidex increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone above basal levels:
-1,0 mg/day Arimidex for 10 weeks in 8 healthy young men (15-22 yr) increases serum T (58%), lh - leutenizing hormone - and FSH - follicle stimulating hormone - concentrations (A1).
-Arimidex for 1 day in 11 young and 9 older men elevates mean lh - leutenizing hormone - concentrations by 2.1-fold (A2).
-10 mg/day Arimidex for 5 days in 9 normal men increases testosterone levels (563 +/- 42 to 817 +/- 81 ng/dl) (A5).
Arimidex decreases estrogen levels (A1-A3, A5):
-1,0 mg/day Arimidex for 10 weeks in 8 young men (15-22 yr) decreases E2 by 48% (A1).
-Arimidex for 1 day in 11 young and 9 older men decreases serum estradiol concentrations by 50% (A2).
-10 mg Arimidex for 5 days in 9 normal men decreases E2 (33 +/- 3 to 14 +/- 1 pg/mL; P: < 0.0005) (A5).
0,5 mg Arimidex provides the same decrease (50%) in E2 concentrations as 1 mg/day (A1).
1 mg/day Arimidex increases testosterone significantly more than 1 mg/twice weekly, but provides no difference in estrogen levels (A3):
-1 mg/day Arimidex for 12 weeks in 12 elderly men increases mean bioavailable testosterone from (99 +/- 31) to (207 +/- 65 ng/dl).
-1 mg/twice weekly Arimidex for 12 weeks in 11 elderly men increases mean bioavailable testosterone (115 +/- 37) to (178 +/- 55 ng/dl).
Blocking of estrogen does not influence body composition or strength:
-1,0 mg/day Arimidex for 10 weeks in 8 young men (15-22 yr) does not significantly change body composition (body mass index, fat mass, and fat-free mass) or in rates of Protein synthesis or degradation; carbohydrate, lipid, or Protein oxidation; muscle strength; calcium kinetics; or bone growth factors concentrations (A1).
Arimidex opposes exogenous testosterone's suppression of lh - leutenizing hormone - and FSH - follicle stimulating hormone - secretion:
-KTCZ lowers serum testosterone concentration (423 +/- 57 ng/dL (15 +/- 2.0 nmo/L) to 58 +/- 8.6 ng/dL (2.0 +/- 0.3 nmol/L). Added transdermal testosterone increases testosterone levels to (607 +/- 57 ng/dL (21 +/- 2.0 nmol/L).
KTCZ alone increases lh - leutenizing hormone - 3-fold and FSH - follicle stimulating hormone - 2.5-fold. Added transdermal testosterone represses the elevated secretion of both lh - leutenizing hormone - and FSH - follicle stimulating hormone - to mid-normal baseline values.
When Arimidex is added to this, it completely opposes exogenous testosterone's suppression of 24-h lh - leutenizing hormone - and FSH - follicle stimulating hormone - secretion. It likewise abolished testosterone-dependent inhibition of 3-h GnRH-stimulated lh - leutenizing hormone - and FSH - follicle stimulating hormone - release (A6).
Arimidex is not effective in the prevention or treatment of gynecomastia:
-Bicalutamide (150 mg/d) + placebo or in combination with (20 mg/d) Nolvadex or Anastrozole (1 mg/d) for 48 weeks was given to 114 men with prostate cancer. gynecomastia developed in 73% of patients in the bicalutamide group, 10% of the bicalutamide-Nolvadex group, and 51% of the bicalutmide-Anastrozole group (A11).
-1 mg Arimidex for 6 months in 80 boys with gynecomastia provided a 38,5% response vs. 31,4% in the placebo group (A12).
-Arimidex for 6 months in 5 boys with gynecomastia provided a decrease of breast size in 4/5 patients, but breast tissue did not dissappear in 4/5 boys (A13).
Side effects Arimidex
-1 mg Arimidex for 6 months in 80 boys was well tolerated (A12).
-Arimidex for 6 months in 5 boys did not show any adverse effects (A13).
Arimidex and lipid profiles:
-Some studies show Anastrozole as generally having little effect on lipids, while others have indicated adverse effects on lipid profiles/increased hypercholesterolaemia (F11).


Femara increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone values (F1-F3)
-7.5-17.5 mg Femara/week for 6 weeks in 10 men with hypogonadism increases lh - leutenizing hormone - (4.5 +/- 0.8 to 14.8 +/- 2.3 U/l) and total testosterone (7.5 +/- 1.0 to 23.8 +/- 3.0 nmol/l) (F2).
Femara increases lh - leutenizing hormone - , FSH - follicle stimulating hormone - and testosterone above basal levels:
-2,5 mg/day Femara for 28 days in 20 healthy men increases lh - leutenizing hormone - (323-339%) and testosterone (99-146%) (F1).
Femara decreases estrogen levels:
-2,5 mg/day Femara for 28 days in 20 healthy men lowers E2 by 46% in young men and 62% in elder men (F1).
-7.5-17.5 mg Femara/week for 6 weeks in 10 men with hypogonadism decreases serum estradiol (120 +/- 20 to 70 +/- 9 pmol/l) (F2).
Femara keeps estradiol levels basal and increases testosterone + GnRH-induced lh - leutenizing hormone - response during testosterone treatment:
-A low-dose testosterone treatment was given to 23 boys with constitutional delay of puberty. Femara keeps estradiol concentrations at pretreatment levels and increases testosterone > 5-fold higher than testosterone alone (F3).
-testosterone treatment was given to 25 boys with dela puberty for 5 months. T concentrations increased by 55% and 17beta-E2 increased by 130% and gonadotropin concentrations were suppressed. Femara keeps 17beta-E2 at pretreatment levels and increases T concentrations 606%. Basal gonadotropin concentration and the GnRH-induced lh - leutenizing hormone - response increased, and the GnRH-induced FSH - follicle stimulating hormone - response did not change (F4).
No studies can be found on the effect of Femara on gynecomastia!
Femara and lipid profiles:
-Letrozole has been associated with adverse effects on lipid profiles in some studies, including BIG 1-98, but short-term data from randomised trials do not show increased cardiovascular morbidity (F11).


A1)http://jcem.endojournals.org/cgi/content/full/85/7/2370
A2)http://www.ncbi.nlm.nih.gov/entrez/q...79&query_hl=14
A3)http://www.ncbi.nlm.nih.gov/entrez/q...05&query_hl=15
A4)http://www.ncbi.nlm.nih.gov/entrez/q...79&query_hl=16
A5)http://www.ncbi.nlm.nih.gov/entrez/q...78&query_hl=18
A6)http://www.ncbi.nlm.nih.gov/entrez/q...60&query_hl=17
A11)http://www.ncbi.nlm.nih.gov/entrez/q...678&query_hl=1
A12)http://www.ncbi.nlm.nih.gov/entrez/q...042&query_hl=1
A13)http://www.ncbi.nlm.nih.gov/entrez/q...427&query_hl=1
F1)http://www.ncbi.nlm.nih.gov/entrez/q...582&query_hl=1
F2)http://www.ncbi.nlm.nih.gov/entrez/q...136&query_hl=1
F3)http://www.ncbi.nlm.nih.gov/entrez/q...531&query_hl=1
F4)http://www.ncbi.nlm.nih.gov/entrez/q...558&query_hl=1
F11)http://www.ncbi.nlm.nih.gov/entrez/q...522&query_hl=3
Gallery of Big'r
__________________
ADMIN/OWNER@Peak-Muscle
liftsiron is online now   Reply With Quote
Links


Old 06-09-2011, 06:21 PM   #2
quez82
Registered User
 
quez82's Avatar
 

Join Date: Jul 2003
Posts: 315
quez82 is on a distinguished road
Did my question bring this up? haha. Been so long since i've talked about all of this. Thanks for the info again.
__________________
Quez82 does not promote the use of anabolic steroids without a doctor's prescription. The information we share is for entertainment purposes only.
quez82 is offline   Reply With Quote
Reply


Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -5. The time now is 10:50 AM.


Powered by: vBulletin Version 3.6.8
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.